Senate Hearing Questions Strength Of FDA Post-Market Surveillance
This article was originally published in The Gray Sheet
Executive Summary
An April 13 Senate hearing billed as a look at the medical device approval process turned into a wide-ranging critique of FDA's post-market surveillance of device safety.